Radiation therapy after conservative breast surgery is an integral part of the treatment of early breast cancer</span><span style="font-family:Verdana;">.</span></span></span>&l...Radiation therapy after conservative breast surgery is an integral part of the treatment of early breast cancer</span><span style="font-family:Verdana;">.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The aim of radiotherapy is</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> to achieve the best coverage of </span><span style="font-family:Verdana;">the</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Planning</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> Target Volume (PTV</span><span style="font-family:Verdana;">),</span><span style="font-family:Verdana;"> while reducing the dose to the Organs at Risk (OAR). Such goals are not always achievable with the conformal three dimensions plans (3DCRT). Recently, </span><span style="font-family:Verdana;">radiation</span><span style="font-family:Verdana;"> oncologist uses Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT)</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">for irradiating the breast. In this study, we compared 3DCRT, IMRT </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> VMAT for left breast cancer patients in terms of PTV coverage, OAR</span><span style="font-family:Verdana;">.</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">We</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> also revised the different dose distribution in 1) different breast volume categories, 2) nodal irradiation versus breast only, and 3) boost versus no boost. Results</span><span style="font-family:Verdana;">:</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> routinely reported dose </span><span style="font-family:Verdana;">constrains</span><span style="font-family:Verdana;"> for the ipsilateral lung and </span><span style="font-family:Verdana;">for</span><span style="font-family:Verdana;"> the heart were not significantly different on comparing the three techniques. While for the contralateral lung, the difference in mean dose was in favor of 3DCRT.</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">In large breast </span><span style="font-family:Verdana;">volume,</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">3DCRT provided a lower Max dose to the contralateral </span><span style="font-family:Verdana;">lung</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">and</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> the</span></span></span><span><span><span style="font-family:""> <span style="font-family:Verdana;">lowest</span><span style="font-family:Verdana;"> mean dose to the contralateral breast when compared to IMRT p < 0. 046</span><span style="font-family:Verdana;">.</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">In</span></span></span><span><span><span style="font-family:""> <span style="font-family:Verdana;">case</span><span style="font-family:Verdana;"> of no nodal irradiation, the contralateral breast </span><span style="font-family:Verdana;">mean</span><span style="font-family:Verdana;"> dose was lower in 3DCRT in comparison to IMRT and VMAT p < 0.037. When boost dose was given, 3DCRT plans had produced a lower Max dose to the contralateral lung p < 0.017. Conclusion</span><span style="font-family:Verdana;">:</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> three techniques (3DCRT, IMRT, and VMAT) can meet the clinical dosimetry demands of radiotherapy for left breast cancer after conservative surgery, as long as the routinely OARs only (heart and ipsilateral lung) </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">are</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> reported. Our study showed that 3CDRT can provide a lower dose to the contralateral organs (breast and lung), </span><span style="font-family:Verdana;">specially</span><span style="font-family:Verdana;">, in case of large breast volumes, no nodal irradiation </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> when a boost </span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">is </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">given</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">.展开更多
To investigate the influence of prophylactic elec-tive nodal irradiation on the therapeutic results of definitive radiotherapy for patients with stage IIIA or stage IIIB unre-sectable non-small-cell lung cancer,55 pat...To investigate the influence of prophylactic elec-tive nodal irradiation on the therapeutic results of definitive radiotherapy for patients with stage IIIA or stage IIIB unre-sectable non-small-cell lung cancer,55 patients with clini-cally inoperable advanced non-small-cell lung cancer were studied.After four cycles of induction chemotherapy,the patients were divided into two groups at random.In one group,the elective nodal irradiation was included in clinical tumor volume(CTV)of definitive radiotherapy(ENI group);and in the other group,elective nodal irradiation was not included in CTV(non-ENI group).For the patients in the ENI group,the mean prescription dose for gross tumor volumes was 58.4 Gy,while for the patients in the non-ENI group,it was 65.8 Gy(P<0.05).The responsive rates were 45.8%and 74.0%(P<0.05),and the rate of the elective nodal failure(ENF)was 4.2%and 11.1%,respectively.Kaplan-Meier analysis showed that the mean local-progression-free survival time was 11.0 and 15.0 months,and one-year local-failure rates were 51.9%and 24.5%(P<0.05).The median overall survival time was 13.0 and 15.0 months,respectively(P=0.084).The one-year survival rates were 55.7%and 72.5%,and two-year survival rates were 0%and 19.9%.There was no significant difference in the occurrences of radiation-associated complications between the two groups.Our results showed that omitting elective nodal irradiation did not result in a high incidence of elective nodal failure.On the contrary,it decreased local failure by increasing prescrip-tion doses to the primary diseases and lymphadenopaphy,and thereby it may further prolong the patients’survival.展开更多
文摘Radiation therapy after conservative breast surgery is an integral part of the treatment of early breast cancer</span><span style="font-family:Verdana;">.</span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The aim of radiotherapy is</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> to achieve the best coverage of </span><span style="font-family:Verdana;">the</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">Planning</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> Target Volume (PTV</span><span style="font-family:Verdana;">),</span><span style="font-family:Verdana;"> while reducing the dose to the Organs at Risk (OAR). Such goals are not always achievable with the conformal three dimensions plans (3DCRT). Recently, </span><span style="font-family:Verdana;">radiation</span><span style="font-family:Verdana;"> oncologist uses Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT)</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">for irradiating the breast. In this study, we compared 3DCRT, IMRT </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> VMAT for left breast cancer patients in terms of PTV coverage, OAR</span><span style="font-family:Verdana;">.</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">We</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> also revised the different dose distribution in 1) different breast volume categories, 2) nodal irradiation versus breast only, and 3) boost versus no boost. Results</span><span style="font-family:Verdana;">:</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> routinely reported dose </span><span style="font-family:Verdana;">constrains</span><span style="font-family:Verdana;"> for the ipsilateral lung and </span><span style="font-family:Verdana;">for</span><span style="font-family:Verdana;"> the heart were not significantly different on comparing the three techniques. While for the contralateral lung, the difference in mean dose was in favor of 3DCRT.</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">In large breast </span><span style="font-family:Verdana;">volume,</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;">3DCRT provided a lower Max dose to the contralateral </span><span style="font-family:Verdana;">lung</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">and</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> the</span></span></span><span><span><span style="font-family:""> <span style="font-family:Verdana;">lowest</span><span style="font-family:Verdana;"> mean dose to the contralateral breast when compared to IMRT p < 0. 046</span><span style="font-family:Verdana;">.</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">In</span></span></span><span><span><span style="font-family:""> <span style="font-family:Verdana;">case</span><span style="font-family:Verdana;"> of no nodal irradiation, the contralateral breast </span><span style="font-family:Verdana;">mean</span><span style="font-family:Verdana;"> dose was lower in 3DCRT in comparison to IMRT and VMAT p < 0.037. When boost dose was given, 3DCRT plans had produced a lower Max dose to the contralateral lung p < 0.017. Conclusion</span><span style="font-family:Verdana;">:</span></span></span></span><span><span><span style="font-family:""> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">The</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> three techniques (3DCRT, IMRT, and VMAT) can meet the clinical dosimetry demands of radiotherapy for left breast cancer after conservative surgery, as long as the routinely OARs only (heart and ipsilateral lung) </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">are</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> reported. Our study showed that 3CDRT can provide a lower dose to the contralateral organs (breast and lung), </span><span style="font-family:Verdana;">specially</span><span style="font-family:Verdana;">, in case of large breast volumes, no nodal irradiation </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> when a boost </span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">is </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">given</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">.
文摘To investigate the influence of prophylactic elec-tive nodal irradiation on the therapeutic results of definitive radiotherapy for patients with stage IIIA or stage IIIB unre-sectable non-small-cell lung cancer,55 patients with clini-cally inoperable advanced non-small-cell lung cancer were studied.After four cycles of induction chemotherapy,the patients were divided into two groups at random.In one group,the elective nodal irradiation was included in clinical tumor volume(CTV)of definitive radiotherapy(ENI group);and in the other group,elective nodal irradiation was not included in CTV(non-ENI group).For the patients in the ENI group,the mean prescription dose for gross tumor volumes was 58.4 Gy,while for the patients in the non-ENI group,it was 65.8 Gy(P<0.05).The responsive rates were 45.8%and 74.0%(P<0.05),and the rate of the elective nodal failure(ENF)was 4.2%and 11.1%,respectively.Kaplan-Meier analysis showed that the mean local-progression-free survival time was 11.0 and 15.0 months,and one-year local-failure rates were 51.9%and 24.5%(P<0.05).The median overall survival time was 13.0 and 15.0 months,respectively(P=0.084).The one-year survival rates were 55.7%and 72.5%,and two-year survival rates were 0%and 19.9%.There was no significant difference in the occurrences of radiation-associated complications between the two groups.Our results showed that omitting elective nodal irradiation did not result in a high incidence of elective nodal failure.On the contrary,it decreased local failure by increasing prescrip-tion doses to the primary diseases and lymphadenopaphy,and thereby it may further prolong the patients’survival.